Ophthotech Corp (OPHT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Ophthotech Corp (OPHT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH63203D
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Ophthotech Corp (Ophthotech) is a biopharmaceutical company that offers novel therapeutics to treat diseases of the back of the eye for age-related macular degeneration. The company's products include Zimura, an anti-complemente is a central component of the complement cascade that is supposed to be used in the development of AMD. It also provides Fovista, an anti-platelet-derived growth factor (PDGF). Ophthotech offers gene therapy research programs, dry age-related macular degeneration and ophthalmic orphan programs. The company utilizes aptamer technology, a single strand of nucleic acid to targets such as PDGF, comparable to a monoclonal antibody. Its Fovista is used to inhibit abnormal new blood vessel growth associated with wet AMD. The company has its operations in New York and Princeton, the US. Ophthotech is headquartered in New York, the US.

Ophthotech Corp (OPHT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ophthotech Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Ophthotech Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Ophthotech Corp, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Ophthotech Raises USD 83.3 Million In Series C Financing 11

Ophthotech Raises Funds Through Venture Financing 13

Ophthotech Raises Funds Through Venture Financing 14

Ophthotech Raises Funds Through Venture Financing 15

Partnerships 16

Ophthotech and University of Pennsylvania Enter into Agreement 16

Ophthotech Enters into Research Agreement with University of Massachusetts Medical School 17

Ophthotech Enters into Agreement with Foundation Fighting Blindness 18

Midatech Pharma Enters into Agreement with Ophthotech 19

International Drug Development Institute Partners with Ophthotech 20

Licensing Agreements 21

Ophthotech Enters into Licensing Agreement with University of Florida Research Foundation and the University of Pennsylvania 21

Ophthotech Amends Licensing Agreement with Novartis 22

Equity Offering 24

Ophthotech Plans to Raise up to USD150 in Public Offering of Securities 24

Ophthotech Completes Public Offering Of Shares For USD 60 Million 25

Ophthotech Completes IPO For USD 192.3 Million 26

Ophthotech Corp-Key Competitors 28

Ophthotech Corp-Key Employees 29

Ophthotech Corp-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Strategy And Business Planning 31

Feb 01, 2017: Ophthotech Announces Strategic Review Plan 31

Financial Announcements 32

Aug 01, 2018: Ophthotech Reports Second Quarter 2018 Financial and Operating Results 32

May 09, 2018: Ophthotech announces Q1 2018 results 34

Feb 27, 2018: Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results 36

Nov 08, 2017: Ophthotech Reports Third Quarter 2017 Financial and Operating Results 38

Jul 26, 2017: Ophthotech Reports Second Quarter 2017 Financial and Operating Results 40

Jul 26, 2017: Ophthotech Q2 net loss decreases 41

May 03, 2017: Ophthotech Reports First Quarter 2017 Financial and Operating Results 42

Feb 28, 2017: Ophthotech Reports Fourth Quarter and Full Year 2016 Financial and Operating Results 43

Corporate Communications 44

Jan 16, 2018: Ophthotech Announces Election of Jane Pritchett Henderson to Its Board of Directors 44

Apr 24, 2017: Ophthotech Announces Leadership Transition Effective July 1, 2017 45

Product News 46

08/22/2018: Scientific data for novel adeno-associated virus gene therapy in rhodopsin-mediated autosomal dominant retinitis pigmentosa published in proceedings of the National Academy of Sciences 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

Ophthotech Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ophthotech Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Ophthotech Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ophthotech Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Ophthotech Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ophthotech Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Ophthotech Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Ophthotech Raises USD 83.3 Million In Series C Financing 11

Ophthotech Raises Funds Through Venture Financing 13

Ophthotech Raises Funds Through Venture Financing 14

Ophthotech Raises Funds Through Venture Financing 15

Ophthotech and University of Pennsylvania Enter into Agreement 16

Ophthotech Enters into Research Agreement with University of Massachusetts Medical School 17

Ophthotech Enters into Agreement with Foundation Fighting Blindness 18

Midatech Pharma Enters into Agreement with Ophthotech 19

International Drug Development Institute Partners with Ophthotech 20

Ophthotech Enters into Licensing Agreement with University of Florida Research Foundation and the University of Pennsylvania 21

Ophthotech Amends Licensing Agreement with Novartis 22

Ophthotech Plans to Raise up to USD150 in Public Offering of Securities 24

Ophthotech Completes Public Offering Of Shares For USD 60 Million 25

Ophthotech Completes IPO For USD 192.3 Million 26

Ophthotech Corp, Key Competitors 28

Ophthotech Corp, Key Employees 29

Ophthotech Corp, Other Locations 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Ophthotech Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17815
Site License
USD 500 INR 35630
Corporate User License
USD 750 INR 53445

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com